MSI2 and diffuse large B-cell lymphoma: Intriguingly, markers lost after MSI2 knockdown including ALDH (Song et al., 2014), side population (Chen et al., 2020), and NOTCH signaling (Hartert et al., 2021) have each been implicated in DLBCL therapy resistance, supporting further assessment of treatment response.